Jacques-François Martin to chair Anergis
This article was originally published in Scrip
Anergis, a clinical-stage biopharmaceutical company developing allergy vaccines, has appointed Jacques-François Martin chair of the board. Mr Martin is currently chair and CEO of Mymetics, and was previously CEO of Chiron Vaccines, now Novartis. He has also served in leadership positions for non-profit organisations and was the first president and CEO of The Vaccine Fund (Bill and Melinda Gates Foundation) from 2000-2005.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.